Pacira BioSciences Urges Shareholder Support in Proxy Battle, Highlights Strong Performance & $200M Buyback
Summary
Pacira BioSciences filed definitive additional proxy materials, urging shareholders to vote for its nominees in the ongoing proxy contest and detailing its strong operational progress, significant share repurchases, and refreshed board.
Key Events
-
Proxy Contest Intensifies
Pacira filed definitive additional proxy materials, urging shareholders to vote for its nominees and against DOMA Perpetual's candidates in the upcoming June 9th Annual Meeting.
-
Strong Operational Performance Highlighted
The company highlighted successful execution of its "5x30 strategy," reporting a 35% stock increase since its launch, record gross margins, and advancements in its product pipeline and partnerships.
-
Significant Share Repurchases
Pacira detailed returning $200 million to stockholders through share repurchases since 2025, reducing outstanding common shares from 47 million to 39 million.
-
New Board Nominee Introduced
Thomas Wiggans, a seasoned biopharmaceutical executive with over 40 years of leadership experience, was nominated to the board.
Analysis
This DEFA14A provides Pacira BioSciences' full letter to shareholders, intensifying its defense against activist investor DOMA Perpetual ahead of the June 9th Annual Meeting. The company strongly advocates for its three board nominees, including new nominee Thomas Wiggans, while criticizing DOMA's candidates as underqualified. The filing highlights the successful execution of Pacira's "5x30 strategy," which has seen the stock rise over 35% and delivered record gross margins. Crucially, Pacira emphasizes its commitment to shareholder returns, detailing $200 million in share repurchases since 2025, which significantly reduced outstanding shares. This communication aims to solidify investor confidence in the current management and strategic direction amidst the contested board election.
At the time of this filing, PCRX was trading at $25.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $18.80 to $27.64. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.